TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27364883

Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic hysterectomy (RALH)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Total abdominal hysterectomy by laparotomy (TAH)
Number of subjects: 137
Study: 24061719

Group type: EXPERIMENTAL
Intervention: CT-based PSI system (group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MRI/X-ray-based PSI system (group B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both PSI systems
Number of subjects: 50
Study: 23201845

Group type: EXPERIMENTAL
Intervention: Dietary vitamin C
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Dietary copper
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: β‐carotene, vitamin E, zinc
Number of subjects: 420
Study: 20839388

Group type: EXPERIMENTAL
Intervention: Codeine (p.o. 30 mg q.d.s., n = 8)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (s.c. 0.30 mg/kg, n = 16)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined MNTX and codeine (same doses and routes, n = 16)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo [s.c. and p.o. (orally), n = 8]
Number of subjects: 48
Study: 17425495

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 16117920

Group type: EXPERIMENTAL
Intervention: Protocols of randomised trials
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Statistically significant outcomes
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Trials with at least one primary outcome changed
Number of subjects: 102
Study: 10930153

Group type: EXPERIMENTAL
Intervention: Triple combination therapy including protease inhibitors (PI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple combination therapy including non-nucleoside reverse transcriptase inhibitors (NNRTI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual nucleoside therapy
Number of subjects: 0
Study: 9058214

Group type: EXPERIMENTAL
Intervention: Limited intentional normovolemic hemodilution (LINH) during the prebypass period until a hematocrit of 34% was obtained, with succinyl-linked gelatin infusion (n = 39)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group with no hemodilution (n = 32)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: LINH group (n = 39)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (n = 32)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Postoperative use of homologous blood products
Number of subjects: 71

Group type: COMPARATOR
Intervention: Total blood loss
Number of subjects: 71
Study: 8372698

Group type: EXPERIMENTAL
Intervention: Slow dawn simulation (gradually increasing illuminance over 45 min peaking at 100 lx)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rapid dawn simulation (light rapidly increasing over a 4 s period to 100 lx)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 16
Study: 3527407

Group type: EXPERIMENTAL
Intervention: levamisole, 2.5 mg/kg, 2 days of each week in addition to chemotherapy
Number of subjects: 97

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 97
Study: 29316902

Group type: EXPERIMENTAL
Intervention: Ankle tape
Number of subjects: 34

Group type: COMPARATOR
Intervention: No ankle tape (control)
Number of subjects: 34
Study: 26775184

Group type: EXPERIMENTAL
Intervention: Midazolam and fentanyl combined as a single solution (group 2, 55 patients)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Midazolam and fentanyl administered separately (group 1, 57 patients)
Number of subjects: 112
Study: 23621672

Group type: EXPERIMENTAL
Intervention: Canadian Occupational Performance Measure (COPM)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Gender comparison
Number of subjects: 152
Study: 21551176

Group type: EXPERIMENTAL
Intervention: Shoulder strapping applied for one month in addition to routine rehabilitation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Routine rehabilitation only
Number of subjects: 14
Study: 18479744

Group type: EXPERIMENTAL
Intervention: Extended-release metoprolol succinate (n=4174)
Number of subjects: 8351

Group type: COMPARATOR
Intervention: Placebo (n=4177)
Number of subjects: 8351
Study: 17133050

Group type: EXPERIMENTAL
Intervention: Fluid-based system
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional ultrasound
Number of subjects: 23

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 23
Study: 12799892

Group type: EXPERIMENTAL
Intervention: Three-port technique
Number of subjects: 200

Group type: COMPARATOR
Intervention: Four-port technique
Number of subjects: 200
Study: 11218055

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study: 9087975

Group type: EXPERIMENTAL
Intervention: Selegiline in addition to levodopa
Number of subjects: 163

Group type: COMPARATOR
Intervention: Levodopa monotherapy
Number of subjects: 163
Study: 8238220

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (mean total dose, 24.8 mg; mean number of injections, 5.0 ± 1.3)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (no 5-fluorouracil)
Number of subjects: 74
Study: 2436011

Group type: EXPERIMENTAL
Intervention: 2.9 g of the amylase inhibitor
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2.0 g of the amylase inhibitor
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29105313

Group type: EXPERIMENTAL
Intervention: Pru p 3-enriched-SLIT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untreated peach allergic patients)
Number of subjects: 0
Study: 26081485

Group type: EXPERIMENTAL
Intervention: EAA mixture with 20% L-Leucine (Group A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: EAA mixture with 40% L-Leucine (Group B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 36
Study: 25311337

Group type: EXPERIMENTAL
Intervention: AdheSE non-etch (self-etch approach)
Number of subjects: 22

Group type: COMPARATOR
Intervention: AdheSE etch (self-etch approach with selective acid-etching of enamel margins)
Number of subjects: 22
Study: 23027230

Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no self-affirmation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low physical self-esteem
Number of subjects: 0
Study: 20823297

Group type: EXPERIMENTAL
Intervention: Suppressing thoughts of thirst
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suppressing aggressive thoughts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suppressing laughter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Belief that suppression is difficult for everybody
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivation to do the suppressed behavior
Number of subjects: 0
Study: 18433921

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (6.5 x 10(9)) 3 times daily for 4 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy controls (n=13)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cirrhotic patients without probiotics (n=8)
Number of subjects: 12
Study: 20076952

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg orally for 5 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16235159

Group type: EXPERIMENTAL
Intervention: BIAsp 70 (70% soluble IAsp and 30% protaminated IAsp)
Number of subjects: 27

Group type: COMPARATOR
Intervention: BIAsp 30 (30% soluble IAsp and 70% protaminated IAsp)
Number of subjects: 27

Group type: COMPARATOR
Intervention: BIAsp 30
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: BIAsp 70
Number of subjects: 27
Study: 11801578

Group type: EXPERIMENTAL
Intervention: AmBisome 3 or 5 mg/kg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abelcet 5 mg/kg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amphocil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipid formulations (general)
Number of subjects: 0
Study: 9670875

Group type: EXPERIMENTAL
Intervention: Aerobic training (T)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 16
Study: 7869686

Group type: EXPERIMENTAL
Intervention: Initial injection of diluted local anesthetic (1:10 with saline)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Full-strength 2% mepivacaine with adrenaline 1:200,000
Number of subjects: 13
Study: 3794867

Group type: EXPERIMENTAL
Intervention: HB-PU umbilical catheters
Number of subjects: 125

Group type: COMPARATOR
Intervention: PVC catheters
Number of subjects: 125
Study: 29424934

Group type: EXPERIMENTAL
Intervention: Individual structured and qualified feedback (FB) after pre-assessment
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 53
Study: 27479106

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy (CBGT) with e-mail support
Number of subjects: 91

Group type: COMPARATOR
Intervention: Cognitive Behavioral Group Therapy (CBGT) without e-mail support
Number of subjects: 91
Study: 24549763

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) with 1,000 impulses
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo group treated with deactivated shock wave applicator
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 26
Study: 22294812

Group type: EXPERIMENTAL
Intervention: 2 nights of total sleep deprivation (TSD) and one night of recovery sleep
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 20043965

Group type: EXPERIMENTAL
Intervention: Tempting, high caloric food choice
Number of subjects: 0

Group type: COMPARATOR
Intervention: No tempting food choice (control)
Number of subjects: 0
Study: 18464752

Group type: EXPERIMENTAL
Intervention: Pre-weight loss obese subjects
Number of subjects: 6

Group type: COMPARATOR
Intervention: Nonobese subjects (Control)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Post-weight loss obese subjects
Number of subjects: 6
Study: 15894962

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 108

Group type: COMPARATOR
Intervention: Calcium acetate
Number of subjects: 108
Study: 13677125

Group type: EXPERIMENTAL
Intervention: 10 g Owen Mumford monofilament sensory testing
Number of subjects: 0
Study: 9892256

Group type: EXPERIMENTAL
Intervention: Bereavement support group intervention
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 166
Study: 9346691

Group type: EXPERIMENTAL
Intervention: Intravenous insulin bolus (666 mU . kg‐1) followed by infusion at 500 mU.m‐2.min‐1 until 3 hours after portal vein unclamping.
Number of subjects: 20

Group type: COMPARATOR
Intervention: No exogenous insulin administered.
Number of subjects: 20
Study: 1816197

Group type: EXPERIMENTAL
Intervention: Enoxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 0
Study: 7080885

Group type: EXPERIMENTAL
Intervention: Home correspondence program conducted entirely by mail
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Mail program with supplemental financial contingency contracts tied to completion of written homework
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Correspondence programs supplemented by homework contracts and regular calls to a telephone answering system
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard behavioral group program
Number of subjects: 87
Study: 28627737

Group type: EXPERIMENTAL
Intervention: ICDAS (IC)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nyvad's (NY)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional Visual Clinical Examination (CVCE)
Number of subjects: 8
Study: 27296819

Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg/formoterol 12 μg
Number of subjects: 590

Group type: COMPARATOR
Intervention: Formoterol 12 μg
Number of subjects: 590
Study: 24532007

Group type: EXPERIMENTAL
Intervention: 600 mg tideglusib
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: 800 mg tideglusib
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 22801818

Group type: EXPERIMENTAL
Intervention: Diagnostic puncture of the renal pelvis
Number of subjects: 148
Study: 20381156

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Psychotherapies
Number of subjects: 372
Study: 18671615

Group type: EXPERIMENTAL
Intervention: Antimicrobial suture (AMS)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional suture (control)
Number of subjects: 61
Study: 15908835

Group type: EXPERIMENTAL
Intervention: MAS XR 10 mg once daily, with 10 mg weekly dose increases to a maximum of 30 mg/d
Number of subjects: 568
Study: 15651745

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 0
Study: 10917210

Group type: EXPERIMENTAL
Intervention: Intratumoral injection of a replication-defective adenoviral expression vector containing wild-type p53
Number of subjects: 6
Study: 9347431

Group type: EXPERIMENTAL
Intervention: ondansetron 100 mcg/kg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: droperidol 75 mcg/kg
Number of subjects: 160

Group type: COMPARATOR
Intervention: metoclopramide 250 mcg/kg
Number of subjects: 160

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 160
Study: 8191134

Group type: EXPERIMENTAL
Intervention: Miocamycin (15 mg/kg/day bid per os)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Benzathine penicillin G (600,000 or 1,200,000 units, single injection)
Number of subjects: 149
Study: 3083712

Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nitroglycerin (NTG)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg orally) with SNP
Number of subjects: 27
Study: 31698336

Group type: EXPERIMENTAL
Intervention: 10,000 steps per day (basic intervention)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 10,000 steps per day and at least 30 minutes in moderate intensity (enhanced intervention)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 30522462

Group type: EXPERIMENTAL
Intervention: Tourniquet use during total knee replacement
Number of subjects: 0
Study: 26796192

Group type: EXPERIMENTAL
Intervention: Midseptal lead positioning
Number of subjects: 226

Group type: COMPARATOR
Intervention: Apical lead positioning
Number of subjects: 226
Study: 24445685

Group type: EXPERIMENTAL
Intervention: 600 mg oral n-acetyl cysteine twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22730694

Group type: EXPERIMENTAL
Intervention: Drug treatment group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Complex treatment group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Tetrandrine combined with whole-lung lavage
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 20556437

Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB) with 5 mL of 0.5% levobupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fast-track general anesthesia (GA) via laryngeal mask airway (LMA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB)
Number of subjects: 60
Study: 18448318

Group type: EXPERIMENTAL
Intervention: k-NN algorithm with feature selection
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: k-NN algorithm with non-binary weights
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Single-variable classifier based on choline-to-NAA abnormality index
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: k-NN results
Number of subjects: 26
Study: 16167284

Group type: EXPERIMENTAL
Intervention: Tobramycin enhanced viscosity ophthalmic solution (3 mg/mL) given twice daily (BID) for 7 days
Number of subjects: 276

Group type: COMPARATOR
Intervention: Tobramycin 0.3% ophthalmic solution (3 mg/mL) given four times daily (QID) for 7 days
Number of subjects: 276
Study: 15307418

Group type: EXPERIMENTAL
Intervention: Asymptomatic Chagas disease patients
Number of subjects: 133
Study: 10087016

Group type: EXPERIMENTAL
Intervention: 300 mg of caffeine consumed as a single dose in the morning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine maintenance doses of 100, 300, and 600 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 mg caffeine/day with lower doses (200, 100, 50, 25, and 0 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 mg/day for 1, 3, 7, or 14 days
Number of subjects: 0
Study: 7612769

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg intravenously (4 doses starting at induction of anaesthesia)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hyoscine transdermally (patch placed behind the ear at 0600 h on the day of operation)
Number of subjects: 100
Study: 2403905

Group type: EXPERIMENTAL
Intervention: Infrared photocoagulation (IRPC)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Bipolar diathermy (BD)
Number of subjects: 102
Study: 363105

Group type: EXPERIMENTAL
Intervention: Timolol maleate
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31608549

Group type: EXPERIMENTAL
Intervention: Tofogliflozin (TOFO)
Number of subjects: 774
Study: 29315187

Group type: EXPERIMENTAL
Intervention: System A
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: System B
Number of subjects: 120
Study: 28033244

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (100,000 units single oral dose)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 120
Study: 23903022

Group type: COMPARATOR
Intervention: 10 mg/kg bolus followed by 1 mg·kg·h infusion (low dose)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: 30 mg/kg bolus followed by 16 mg·kg·h infusion (high dose)
Number of subjects: 569
Study: 21923569

Group type: EXPERIMENTAL
Intervention: Support group intervention at the Foundation Lustgården Mälardalen, lasting one week on a residential basis followed by four days of follow-up two months later.
Number of subjects: 382

Group type: COMPARATOR
Intervention: Standard follow‐up routines (Control group)
Number of subjects: 382
Study: 19937152

Group type: EXPERIMENTAL
Intervention: Postbariatric abdominoplasty
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control procedures (never obese women)
Number of subjects: 80
Study: 18689382

Group type: EXPERIMENTAL
Intervention: 100 microg 1 time/d
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: 25 microg 4 times/d
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: 400 microg 1 time/d
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: 100 microg 4 times/d
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: 4000 microg 1 time/d
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: 4000 microg 1 time/wk
Number of subjects: 1108

Group type: COMPARATOR
Intervention: Cessation of folic acid
Number of subjects: 1108
Study: 15899163

Group type: EXPERIMENTAL
Intervention: 105 mg of elemental iron daily p.o.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 105 mg of elemental iron daily and 5 mg of folic acid daily p.o.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No vitamin supplements (control group)
Number of subjects: 0
Study: 14565892

Group type: EXPERIMENTAL
Intervention: Pure self-help (without guidance)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Guided self-help (with guidance)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Treatment completers (N = 18)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Follow-up (6 months post-treatment)
Number of subjects: 31
Study: 10037634

Group type: EXPERIMENTAL
Intervention: Vitamin A (7000 micrograms retinol equivalents)
Number of subjects: 44646

Group type: EXPERIMENTAL
Intervention: Beta carotene (42 mg, or 7000 micrograms retinol equivalents)
Number of subjects: 44646

Group type: EXPERIMENTAL
Intervention: Combined vitamin A or beta carotene
Number of subjects: 44646

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44646
Study: 8650042

Group type: EXPERIMENTAL
Intervention: d-penicillamine treatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Other liver diseases (control group)
Number of subjects: 9
Study: 2180090

Group type: EXPERIMENTAL
Intervention: 50 mg miglitol
Number of subjects: 11
Study: 7011163

Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation (TNS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no TNS)
Number of subjects: 100
Study: 6338889

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 30854700

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori population screening and eradication
Number of subjects: 8658
Study: 30144629

Group type: EXPERIMENTAL
Intervention: Standard In-Office Cognitive Processing Therapy (CPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-Home Telebehavioral Health CPT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-Home CPT (provider delivers treatment in participant's home)
Number of subjects: 0
Study: 26754749

Group type: EXPERIMENTAL
Intervention: HPC + trehalose
Number of subjects: 2532

Group type: COMPARATOR
Intervention: SSS + sucrose
Number of subjects: 2532
Study: 24126617

Group type: EXPERIMENTAL
Intervention: Train-of-four (TOF) monitoring
Number of subjects: 44
Study: 22244363

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient-fortified biscuits (FB)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation (SUP)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 403
Study: 20102884

Group type: EXPERIMENTAL
Intervention: Plasminogen activator inhibitor-1 (PAI-1) antigen
Number of subjects: 2321

Group type: EXPERIMENTAL
Intervention: PAI-1 activity
Number of subjects: 2321

Group type: EXPERIMENTAL
Intervention: PAI-1 to tissue-type plasminogen activator ratio
Number of subjects: 2321

Group type: EXPERIMENTAL
Intervention: D-dimer
Number of subjects: 2321

Group type: EXPERIMENTAL
Intervention: Fibrinogen level
Number of subjects: 2321

Group type: EXPERIMENTAL
Intervention: Tissue-type plasminogen activator antigen
Number of subjects: 2321
Study: 17375984

Group type: EXPERIMENTAL
Intervention: Recombinant human porphobilinogen deaminase (P 9808) at doses of 0.5, 1, 2, and 4 mg/kg bodyweight
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Recombinant human porphobilinogen deaminase (P 9808)
Number of subjects: 40